2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5269 Longitudinal bone marrow genomic profiling defines persistent tumor genotypes following anti-CD20 monotherapy in follicular lymphoma

Julia Christina Kuehn, MD, Alicia Beyou2, Simon Leonard3, Chih Long Liu, PhD4, Feng Tian, PhD5, Navika Shukla, MD6, Guillaume Cartron, MD7, Maximilian Diehn, MD, PhD8, Karin Tarte, PhD, PharmD9, Sandrine Roulland, PhD, PharmD10, Ash A. Alizadeh, MD, PhD11
1 Stanford University, Stanford, California, United States
2 Aix Marseille Université, CNRS, INSERM, Marseille, France
3 UMR 1236, Univ Rennes, Rennes, France
4 Stanford University, Stanford, California, United States
5 Stanford University, Stanford, California, United States
6 Stanford University, Stanford, California, United States
7 University Hospital of Montpellier, Montpellier, France
8 Stanford University, Stanford, California, United States
9 UMR 1236, Univ Rennes, Rennes, France
10 Aix Marseille Université, CNRS, INSERM, Marseille, France
11 Stanford University, Stanford, California, United States

Introduction:

Residual disease in follicular lymphoma (FL) is increasingly thought to be sustained by rare therapy-tolerant B cells that persist despite clinical remission and later seed relapse, yet the cellular programs enabling their persistence in patients remain poorly defined. Prior longitudinal single-cell analyses of paired pre/post-rituximab bone marrow (BM) samples have mapped persister FL B-cell states and traced persistence to ancestral cancer precursor/persister cell (CPC)-like subclones (Beyou et al., 2023, Blood, Tarte et al., 2025, Blood). Here, we build on this framework by performing ultradeep DNA sequencing of matched BM samples before and after rituximab monotherapy to define the mutational profiles and clonotypes underlying persistent BM-resident B cells.

Methods:

Paired BM aspirates from 10 treatment-naïve patients enrolled in the phase III FLIRT trial (NCT02303119) were collected at baseline and 12 months after rituximab monotherapy, and profiled by CAPP-Seq for ultra-deep, targeted capture next-generation duplex sequencing (median depth across samples: 7388; Newman et al., 2016, NBT and Chabon et al., 2021, Nature). Baseline samples were used to first establish each patient somatic mutation profile. These variants were subsequently tracked in matched post-treatment samples using a tumor-informed Monte Carlo–based approach for low–allele fraction minimal residual disease (MRD) detection and confidence estimation, tuned for 80% specificity (Newman et al., 2014, Nat Med). In parallel, clonotypes previously defined by single-cell B-cell receptor (BCR) sequencing were traced longitudinally to relate mutational persistence to clonal architecture using MIXCR (Bolotin et al., 2015, Nat Methods) and SABER (Shukla et al., 2020, Blood). Copy-number alterations were additionally assessed from the sequencing data to provide complementary genomic context using CANARy (Palomino-Mosquera et al., 2021, Blood).

Results:

At diagnosis, ultra-deep sequencing of BM identified a characteristic lymphoma-associated mutational landscape, with BCL2 (50%), CREBBP (40%), KMT2D (40%), and IGLL5 (50%) variants representing the most frequent alterations. Notably, 9 of 10 patients also harbored mutations in genes commonly affected by clonal hematopoiesis (CH), including DNMT3A, TET2, and TP53. At 12 months post-rituximab (M12), 90% of morphologically uninvolved samples with a t(14;18) translocation detectable by quantitative PCR at levels of 10⁻⁴ to 10⁻⁵ retained significantly detectable case-specific variants including those driven by aberrant somatic hypermutation (aSHM). However, while the variant allele fraction (VAF) of pathogenic lymphoma-associated variants declined in all but one patient (median decrease: 49%), the CH-associated VAFs remained largely stable after anti-CD20 therapy. CREBBP and KMT2D variants were undetectable at M12 in all cases, while KLHL6 and IGLL5 mutations were more likely to persist. Tumor BCR clonotypes were detectable in all pretreatment BM samples and remained traceable in 33% of M12 samples, with clonotype fractions strongly correlating with median VAFs. The SHM-associated variant burden decreased relative to pathogenic variants from baseline to M12 in all patients, consistent with preferential clearance of SHM and persistence of a smaller set of tumor-associated variants by anti-CD20 monotherapy.

Conclusion:

These data reveal that a subset of tumor-derived mutations and BCR clonotypes persists in the BM 12 months after rituximab despite overall molecular response. Together, these persistence patterns suggest that residual BM-resident B cells represent a genomically definable population that may underpin long-term disease maintenance.

Julia Christina Kuehn, MD: No relevant conflicts of interest to declare.